Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer - Zhao, Ze-Rui; Yang, Chao-Pin; Chen, Si; Yu, Hui; Lin, Yong-Bin; Lin, Yao-Bin; Qi, Han; Jin, Jie-Tian; Lian, Shan-Shan; Wang, Yi-Zhi; You, Jin-Qi; Zhai, Wen-Yu; et al. (Oncoimmunology, 2021)
Keywords: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; chemotherapy; Humans; immunotherapy; Lung cancer; Lung Neoplasms - drug therapy; neoadjuvant; Neoadjuvant Therapy; toripalimab; neoadjuvant; chemotherapy; Lung cancer; immunotherapy; toripalimab